Report Information More information from: https://www.wiseguyreports.com/reports/2258212
Pyelonephritis - Pipeline Review, H2 2017 Report / Search Code: WGR2258212
Price
Description:
1-user PDF : $ 2000.0
Publish Date: 12 September, 2017
Site PDF : $ 4000.0
Enterprise PDF : $ 6000.0
Pyelonephritis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H2 2017, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape. Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 5, 2 and 1 respectively. Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis
(Infectious Disease) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Contents:
Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Pyelonephritis - Overview Pyelonephritis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Pyelonephritis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Pyelonephritis - Companies Involved in Therapeutics Development Achaogen Inc AstraZeneca Plc Meiji Seika Pharma Co Ltd Merck & Co Inc MerLion Pharmaceuticals Pte Ltd The Medicines Company Zavante Therapeutics Inc Pyelonephritis - Drug Profiles (avibactam + ceftazidime) - Drug Profile Product Description Mechanism Of Action R&D Progress (ceftolozane sulfate + tazobactam sodium) - Drug Profile Product Description Mechanism Of Action R&D Progress (meropenem + vaborbactam) - Drug Profile Product Description Mechanism Of Action R&D Progress AAI-101 - Drug Profile Product Description Mechanism Of Action R&D Progress finafloxacin - Drug Profile Product Description Mechanism Of Action R&D Progress fosfomycin tromethamine - Drug Profile Product Description Mechanism Of Action R&D Progress
nacubactam - Drug Profile Product Description Mechanism Of Action R&D Progress plazomicin sulfate - Drug Profile Product Description Mechanism Of Action R&D Progress Pyelonephritis - Dormant Projects Pyelonephritis - Discontinued Products Pyelonephritis - Product Development Milestones Featured News & Press Releases Jun 05, 2017: Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016 Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam) Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016 Jun 02, 2016: Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections Jun 02, 2016: Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin Apr 07, 2016: Merck To Present Data on ZERBAXA at ECCMID 2016 Feb 22, 2016: New Antibiotic Against Drug-Resistant Bacteria Now Available Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM) Jun 18, 2014: MerLion completes recruitment in Finafloxacin phase II cUTI trial Aug 22, 2013: FDA Grants Qualified Infectious Disease Product Designation and Fast Track Status for MerLion Pharma’s Lead Antibacterial Candidate Finafloxacin Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Tables Number of Products under Development for Pyelonephritis, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pyelonephritis - Pipeline by Achaogen Inc, H2 2017 Pyelonephritis - Pipeline by AstraZeneca Plc, H2 2017 Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017 Pyelonephritis - Pipeline by Merck & Co Inc, H2 2017 Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017 Pyelonephritis - Pipeline by The Medicines Company, H2 2017 Pyelonephritis - Pipeline by Zavante Therapeutics Inc, H2 2017 Pyelonephritis - Dormant Projects, H2 2017 Pyelonephritis - Discontinued Products, H2 2017 List of Figures Number of Products under Development for Pyelonephritis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
wiseguyreports.com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349